**INDICATIONS**

- **JUVÉDERM VOLUMA**® XC injectable gel is indicated for deep (subcutaneous and/or supraperiosteal) injection for cheek augmentation to correct age-related volume deficit in the mid-face in adults over the age of 21.

- **JUVÉDERM Ultra XC and JUVÉDERM Ultra Plus XC** injectable gels are indicated for injection into the mid-to-deep dermis for correction of moderate to severe facial wrinkles and folds (such as nasolabial folds).

- **JUVÉDERM VOLLURE™ XC** injectable gel is indicated for injection into the mid-to-deep dermis for correction of moderate to severe facial wrinkles and folds (such as nasolabial folds) in adults over the age of 21.

- **JUVÉDERM VOLBELLA® XC** injectable gel is indicated for injection into the lips for lip augmentation and for correction of perioral rhytids in adults over the age of 21.

**IMPORTANT INFORMATION**

Please see Important Safety Information on reverse side.
**BEFORE THEY GO…** Invite patients to make an appointment to discuss their personalized treatment plan.

**TIPS FOR TALKING TO PATIENTS:**

These are their top concerns:

**“I’m afraid I won’t LOOK LIKE ME.”**

You say:

- You will still look like yourself—not fake or “done”
- Take a look at some before-and-after photos so you can see real results
- We only recommend treatments that we think will give you natural-looking results

Fact:

A healthcare professional’s recommendation is the biggest factor driving patients to receive their first treatment with JUVÉDERM® (n = 88).\(^{11}\)

**“I don’t want to KEEP COMING BACK for treatment.”**

You say:

- Repeat treatments may be needed to maintain desired results. They usually require less product\(^{2,5,8}\)
- The Brilliant Distinctions® Program allows you to earn points and save on repeat treatments

Fact:

Product duration is a key driver for patients.\(^{15}\)

**“I’m not sure it’s worth the COST.”**

You say:

- JUVÉDERM® VYCROSS® technology fillers* are the longest-lasting hyaluronic acid fillers within each indicated facial area\(^{2,5,8,12-18}\)
- Consider the value of your results over 1 year—or more, for some products!\(^{2,5,7,8}\)

Fact:

84\% (n = 110) of patients are willing to pay more for a product that lasts 6 months longer.\(^19\)

**IMPORTANT SAFETY INFORMATION**

**CONTRAINDICATIONS**

These products should not be used in patients who have severe allergies, marked by a history of anaphylaxis or history of multiple severe allergies, and should not be used in patients with a history of allergies to Gram-positive bacterial proteins or lidocaine contained in these products.

**WARNINGS**

- Do not inject into blood vessels. Introduction of these products into the vasculature may lead to embolization, Gram-positive bacterial proteins or lidocaine contained in these products.

**PRECAUTIONS**

- In order to minimize the risk of potential complications, these products should only be used by healthcare professionals who have appropriate training, experience, and knowledge of facial anatomy.

- Healthcare professionals are encouraged to discuss the potential risks of subcutaneous injections with their patients prior to treatment and ensure that patients are aware of signs and symptoms of potential complications.

- The safety and effectiveness for the treatment of periorbital regions other than the mid-face with JUVÉDERM VOLUMA® XC, facial wrinkles and folds with JUVÉDERM® Ultra XC, JUVÉDERM® Ultra Plus XC, and JUVÉDERM VOLBELLA™ XC and the lips and perioral area with JUVÉDERM® Ultra XC and JUVÉDERM VOLBELLA™ XC have not been established in controlled clinical studies.

- As with all transcutaneous procedures, dermal filler implantation carries a risk of infection. Follow standard precautions associated with injectable materials.

- The safety for use during pregnancy, in breastfeeding females, and in patients with known susceptibility to keloid formation, hypertrophic scarring, and pigmentation disorders has not been studied.

- The safety for use of JUVÉDERM VOLUMA® XC in patients under 35 or over 65 years, JUVÉDERM VOLLURE™ XC and JUVÉDERM VOLBELLA™ XC in patients under 22 years has not been established.

- Use caution in patients on immunosuppressive therapy.

- Patients who are using products that can prolong bleeding (such as aspirin, nonsteroidal anti-inflammatory drugs, and warfarin) may experience increased bruising or bleeding at treatment sites.

**ADVERSE EVENTS**

The most commonly reported side effects for JUVÉDERM® injectable gels were injection-site reddening, swelling, pain, tenderness, firmness, lumps/bumps, bruising, discoloration, and itching. For JUVÉDERM VOLBELLA™ XC, they were predominantly mild or moderate, with duration of 14 days or less; and for JUVÉDERM VOLUMA® XC, they were predominantly mild or moderate, with duration of 30 days or less.

To report an adverse reaction with any product in the JUVÉDERM® Collection, please call Allergan at 1-800-433-8871. Please visit JuvdermDU.com for more information.

Products in the JUVÉDERM® Collection are available by prescription only.

---

Allergan. All rights reserved. All trademarks are the property of their respective owners. Juvaderm.com/professional

---

\(^{11}\)VYCROSS® is a registered trademark of Allergan, Inc., used on JUVÉDERM VOLUMA® XC, JUVÉDERM VOLLURE™ XC, and JUVÉDERM VOLBELLA™ XC.